Show simple item record

dc.contributor.authorOhm, Milou
dc.contributor.authorvan Rooijen, Debbie M
dc.contributor.authorBonačić Marinović, Axel A
dc.contributor.authorvan Ravenhorst, Mariëtte B
dc.contributor.authorvan der Heiden, Marieke
dc.contributor.authorBuisman, Anne-Marie
dc.contributor.authorSanders, Elisabeth A M
dc.contributor.authorBerbers, Guy A M
dc.date.accessioned2020-11-12T16:04:45Z
dc.date.available2020-11-12T16:04:45Z
dc.date.issued2020-10-25
dc.identifier.issn2076-393X
dc.identifier.pmid33113834
dc.identifier.doi10.3390/vaccines8040624
dc.identifier.urihttp://hdl.handle.net/10029/624496
dc.description.abstractNeisseria meningitidis is often asymptomatically carried in the nasopharynx but may cause invasive meningococcal disease, leading to morbidity and mortality. Meningococcal conjugate vaccinations induce functional protective antibodies against capsular antigens, but seroprotection wanes over time. We measured functional antibody titers five years after administration of a single dose of the meningococcal ACWY-polysaccharide-specific tetanus toxoid-conjugated (MenACWY-TT) vaccine in adolescents and middle-aged adults in the Netherlands, using the serum bactericidal antibody with baby rabbit complement (rSBA) assay. Protection was defined as rSBA titer ≥8. The meningococcal ACWY-specific serum IgG concentrations were measured with a multiplex immunoassay. Duration of protection was estimated by a bi-exponential decay model. Sufficient protection for MenC, MenW, and MenY was achieved in 94-96% of the adolescents five years postvaccination, but, in middle-aged adults, only in 32% for MenC, 65% for MenW and 71% for MenY. Median duration of protection for MenCWY was 4, 14, and 21 years, respectively, in middle-aged adults, while, in adolescents, it was 32, 98, and 33 years. Our findings suggest that adolescents, primed in early childhood with MenC conjugate vaccination, remain sufficiently protected after a single dose of MenACWY-TT vaccine. Middle-aged adults without priming vaccination show fast waning of antibodies, particularly MenC, for which protection is lost after four years.en_US
dc.language.isoenen_US
dc.subjectNeisseria meningitidisen_US
dc.subjectadolescentsen_US
dc.subjectlong-term protectionen_US
dc.subjectmiddle-aged adultsen_US
dc.subjectquadrivalent meningococcal vaccineen_US
dc.subjectserum bactericidal antibody assayen_US
dc.titleDifferent Long-Term Duration of Seroprotection against in Adolescents and Middle-Aged Adults after a Single Meningococcal ACWY Conjugate Vaccination in The Netherlands.en_US
dc.identifier.journalVaccines 2020; 8(4):e624en_US
dc.source.journaltitleVaccines


This item appears in the following Collection(s)

Show simple item record